Cantor Fitzgerald Remains Bullish on Perrigo (PRGO) Despite Guidance Cut
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Perrigo Co. (PRGO) PT Lowered to $67 at RBC Capital
August 10, 2018 9:07 AM EDTRBC Capital lowered its price target on Perrigo Co. (NYSE: PRGO) to $67.00 (from $89.00) while maintaining a Sector Perform rating.
... MorePerrigo (PRGO) Tops Q2 EPS by 3c, FY EPS Guidance Misses Views
August 9, 2018 6:19 AM EDTPerrigo (NYSE: PRGO) reported Q2 EPS of $1.22, $0.03 better than the analyst estimate of $1.19. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.23 billion.
GUIDANCE:
Perrigo sees FY2018 EPS of $4.75-$4.95, versus the consensus of $5.20.
For earnings history and earnings-related data on Perrigo (PRGO) click here.
... MorePerrigo (PRGO) to Separate Prescription Pharmaceuticals Business
August 9, 2018 6:17 AM EDTPerrigo Company plc (NYSE: PRGO) today announced that its Board of Directors approved a plan to separate the Company's Prescription Pharmaceuticals (Rx) business following the Company's previously announced strategic portfolio review. Continuing its focus on enhancing shareholder value, the Board believes a separation of the Rx business will better enable this unique asset to capitalize on its platform of differentiated generic pharmaceutical products and allows Perrigo to focus on expanding its leading consumer business. The Board will consider all value-enhancing options, including a possible tax-efficient separation to shareholders, a sale or... More
Perrigo plans to separate prescription pharma business
August 9, 2018 1:04 AM EDTBy Tamara Mathias
(Reuters) - Perrigo Co Plc (NYSE: PRGO) said on Thursday it would separate its generics prescription business, which has been a drag on results, to focus on consumer healthcare following a strategic review, sending the drugmaker's shares down about 8 percent.
Generic drugmakers such as Perrigo, Mylan (NASDAQ: MYL) and Teva Pharmaceutical Industries (NYSE: TEVA) have suffered over the past few years as price erosion has pressured... More
